New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for ...

The third ALS treatment to be given FDA approval, following Mitsubishi Tanabe’s Radicava ($170,000 per year) and generic drug riluzole – Relyvrio is priced at around $12,500 per 28-day ...

“has demonstrated the greatest therapeutic benefit seen to date in an animal model” of ALS, the company says on its website.

Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...

SAVANNAH, GEORGIA — Current disease-modifying therapies for amyotrophic lateral sclerosis (ALS) don’t extend lifespans by much, but several drug options are available, nerve specialists learned.

Glioblastoma is the most common – and the most malignant – primary brain tumor in adults. It's aggressive and incurable. Even with treatment including surgical removal and chemotherapy, the ...

Drugs used to slow Amyotrophic lateral sclerosis (ALS) progression may also suppress self-renewing cancerous stem cells in grade 4 glioblastoma, the most aggressive and incurable brain tumor in ...